Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 12/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243237 | 0.86 | P2RX3 (0.46) | WDR5F2P2RX3P2RX2 | |
| SCHEMBL10243110 | 0.84 | WDR5 (0.40) | WDR5F2KMT2A | |
| SCHEMBL10243306 | 0.82 | WDR5 (0.39) | WDR5F2KMT2AMEN1P2RX3 | |
| SCHEMBL10243094 | 0.82 | WDR5 (0.40) | WDR5F2 | |
| SCHEMBL10243066 | 0.82 | WDR5 (0.49) | WDR5TDP1P2RX3P2RX2 | |
| SCHEMBL10243059 | 0.82 | P2RX3 (0.45) | KMT2AP2RX3P2RX2 | |
| SCHEMBL10243042 | 0.82 | DGAT2 (0.46) | WDR5KMT2AMEN1P2RX3P2RX2 | |
| SCHEMBL10243161 | 0.82 | CNR1 (0.47) | WDR5F2KMT2AMEN1 | |
| SCHEMBL10242972 | 0.82 | DGAT2 (0.46) | WDR5KMT2AMEN1P2RX3P2RX2 | |
| SCHEMBL10243086 | 0.82 | PHGDH (0.41) | WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8846945-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | DILLON MICHAEL PATRICK (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846945-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | DILLON MICHAEL PATRICK (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | DILLON MICHAEL PATRICK (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | DILLON MICHAEL PATRICK (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193368-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193368-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | P2RX2, P2RX3, TPX2 | WDR5 2162/4885F2 3117/4885KMT2A 1691/4885 |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | WDR5 1337/4885F2 2884/4885KMT2A 2876/4885 |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | P2RX2, P2RX3, TPX2 | WDR5 2140/4885F2 3036/4885KMT2A 1652/4885 |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | WDR5 1337/4885F2 2884/4885KMT2A 2876/4885 |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | P2RX3, P2RX2, P2RX5 | WDR5 1337/4885F2 2884/4885KMT2A 2876/4885 |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX5 | WDR5 1337/4885F2 2884/4885KMT2A 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.